Lung cancer is the leading cause of cancer-related mortality worldwide. Although the
PI3K/Akt/mTOR signaling pathway has recently been considered as one of the most altered …

The epidermal growth factor receptor (EGFR) is a kind of receptor tyrosine kinase (RTK) that
plays a critical role in the initiation and development of malignant tumors via modulating …

Background Several mechanisms including abnormal activation of PI3K-AKT-mTOR
pathway have been proved to generate acquired resistance to epidermal growth factor …

Mammalian target of rapamycin (mTOR) is a protein serine/threonine kinase that was initially
identified as the cellular target of rapamycin. This kinase regulates cell growth, proliferation …

SUMMARY The PI3K/AKT/mTOR pathway is commonly activated in non-small-cell lung
cancer. It plays important roles in promoting oncogenesis in lung cancer and mediating …

Background Enhanced phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of
rapamycin (mTOR) pathway is one of the key adaptive changes accounting for epidermal …

Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …

Oncogenic KRAS mutations comprise the largest subset of lung cancer defined by genetic
alterations, but in the clinic no targeted therapies are available that effectively control …

In-frame fusion KIF5B (the-kinesin-family-5B-gene)-RET transcripts have been characterized
in 1–2% of non-small cell lung cancers and are known oncogenic drivers. The RET tyrosine …

Non-small cell lung cancer (NSCLC) with RAS-mutant gene has been the most difficult
obstacle to overcome. Over 25% of muted lung adenocarcinomas have RAS mutation. The …